Stromal tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: a single-center real-world study
2024

Impact of Chemotherapy Regimens on Breast Cancer Response

Sample size: 450 publication 10 minutes Evidence: moderate

Author Information

Author(s): Soong June Bae, Jee Hung Kim, Min Ji Kim, Kook Yoonwon, Baek Seung Ho, Kim Jung Hyun, Moon Sohyun, Lee Seung Eun, Jeong Joon, Cha Yoon Jin, Ahn Sung Gwe

Primary Institution: Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

Hypothesis

Does the addition of carboplatin and pembrolizumab to neoadjuvant chemotherapy improve pathologic complete response rates in triple-negative breast cancer patients?

Conclusion

The addition of pembrolizumab significantly increased the pathologic complete response rate in lymphocyte-predominant breast cancer, while carboplatin improved response in non-lymphocyte-predominant cases.

Supporting Evidence

  • Pathologic complete response rates were 32% in non-carboplatin, 57% in carboplatin, and 64% in pembrolizumab groups.
  • 20.4% of patients had lymphocyte-predominant breast cancer.
  • High levels of stromal tumor-infiltrating lymphocytes were correlated with higher pCR rates.

Takeaway

This study looked at how different chemotherapy treatments help patients with a type of breast cancer called triple-negative. It found that adding certain medicines can help more patients get better.

Methodology

A retrospective cohort study analyzing 450 TNBC patients treated with neoadjuvant chemotherapy and evaluating sTIL levels.

Potential Biases

Potential biases in patient selection and retrospective data collection.

Limitations

The study had a relatively small cohort for the pembrolizumab group and did not analyze survival outcomes due to recent treatment.

Participant Demographics

Among the 450 patients, 41.4% were aged ≥50 years, and 41.8% had histologic grade III tumors.

Statistical Information

P-Value

p<0.001

Confidence Interval

95% CI, 1.64–4.57 for carboplatin; 95% CI, 2.20–7.16 for pembrolizumab

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/s13058-024-01944-0

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication